BMO Capital Markets analyst Evan David Seigerman reiterated an Outperform rating on Merck & Company, Inc. (NYSE: MRK), with a price target of $132.
Merck's developing cardiovascular portfolio, advancements in I&I through the Prometheus transaction, and partnership with Daiichi are likely to position the company to grow through its Keytruda LOE, according to Seigerman.
These developments add to the company's top line for several years.
Merck plans to acquire Caraway Therapeutics, a private Cambridge-based biotech company with numerous preclinical small-molecule assets and novel approaches targeting genetically Full story available on Benzinga.com